Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 10-Jun-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 10-Jun-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg